GLP-1 side effects and 'Ozempic face': separating TikTok from clinical data
Quick answer
This video contains no clinical claims about GLP-1 receptor agonists or any medical topic. The transcript consists entirely of non-substantive audio fragments with no health-related content. No fact-check of specific medical assertions is possible from this video, though the creator operates in a content category where misinformation about semaglutide and tirzepatide is common.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @brittany_joanna actually say?
Honestly? Not much. The transcript from this video amounts to a string of filler phrases: "Like it if she ain't say it shit. It's the lamest thing. Hey ya ya ya ya!" There are no health claims here, no statements about GLP-1 medications, weight loss, dosing, or anything medically relevant. This appears to be a reaction clip, possibly lip-syncing or responding to another video's audio, with no substantive content to evaluate on its merits.
This kind of video is extremely common on TikTok in the GLP-1 space. Creators react to other content, drop relatable commentary, or post audio clips that resonate with their audience without actually saying anything specific. The caption is just an emoji. There are no hashtags providing additional context. With 20,900 views, it found an audience, but it didn't give them any information worth checking.
Does the science back this up?
There is nothing to fact-check scientifically. No claim about semaglutide, tirzepatide, liraglutide, or any GLP-1 receptor agonist was made. No mechanism was described. No outcome was promised. The video contains zero medical content, which means it cannot be evaluated against clinical literature.
That said, the broader GLP-1 content ecosystem on TikTok is worth addressing here. A 2023 analysis published in the Journal of Medical Internet Research (Trinh et al., 2023) found that a significant portion of weight-loss related TikTok content contains misleading or unsubstantiated claims. Reaction videos like this one tend to be lower-risk from a misinformation standpoint, but they also contribute to a culture where engagement replaces education. Getting 20,000 views on content that communicates nothing is a feature of the algorithm, not a marker of usefulness to patients trying to understand their medications.
What did they get wrong (or right)?
Neither category applies in any meaningful way. You cannot get something wrong if you didn't say anything factual, and you cannot get credit for accuracy when no claim was made. The creator did not spread misinformation about GLP-1 drugs, which is genuinely worth noting given how much bad information circulates in this category.
What we can say is that this video is a missed opportunity. People who follow GLP-1 creators on TikTok are often patients managing obesity, type 2 diabetes, or metabolic conditions. They are frequently confused about how these medications work, what side effects to expect, and how compounded versions differ from brand-name drugs like Ozempic or Wegovy. A creator with nearly 21,000 views on a single video has real reach. Using that reach to post "hey ya ya ya" is a choice, and it is not a particularly useful one for an audience that may genuinely need guidance.
What should you actually know?
If you landed here looking for real information about GLP-1 medications, here is what the evidence actually shows. GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) are among the most studied weight-management drugs in recent history. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide produced up to 22.5% mean body weight reduction over 72 weeks. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg produced approximately 14.9% weight reduction.
These are not cures. They work while you take them. Discontinuation is associated with weight regain in most patients, as documented in the STEP 4 withdrawal study (Rubino et al., 2021, JAMA). Compounded versions of these medications are not equivalent to FDA-approved branded drugs. They have not undergone the same safety and efficacy review process, and patients should discuss the distinction with a licensed clinician before making any decisions.
- GLP-1 medications require a prescription and ongoing clinical supervision.
- Side effects including nausea, vomiting, and gastrointestinal discomfort are common, particularly during dose escalation.
- No TikTok video, including this one, replaces a conversation with your prescriber.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 side effects and 'Ozempic face': separating TikTok from clinical data, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
This video contains no clinical claims about GLP-1 receptor agonists or any medical topic.
FormBlends verdict
This video contains no clinical claims about GLP-1 receptor agonists or any medical topic. The transcript consists entirely of non-substantive audio fragments with no health-related content. No fact-check of specific medical assertions is possible from this video, though the creator operates in a content category where misinformation about semaglutide and tirzepatide is common.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video contains no clinical claims about GLP-1 receptor agonists or any medical topic. The transcript consists entirely of non-substantive audio fragments with no health-related content. No fact-check of specific medical assertions is possible from this video, though the creator operates in a content category where misinformation about semaglutide and tirzepatide is common.
- This video makes zero medical claims about GLP-1 medications, so there is nothing to fact-check on clinical grounds.
- TikTok GLP-1 content overall carries real misinformation risk: a 2023 JMIR analysis (Trinh et al.) found a substantial share of weight-loss TikTok content is unsubstantiated.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- This video makes zero medical claims about GLP-1 medications, so there is nothing to fact-check on clinical grounds.
- TikTok GLP-1 content overall carries real misinformation risk: a 2023 JMIR analysis (Trinh et al.) found a substantial share of weight-loss TikTok content is unsubstantiated.
- Semaglutide 2.4mg produced roughly 14.9% mean weight reduction in the STEP 1 trial (Wilding et al., 2021, NEJM), one of the most cited benchmarks in the space.
- Tirzepatide produced up to 22.5% mean weight reduction in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), currently among the strongest clinical results for any obesity medication.
- Weight regain after stopping GLP-1 therapy is well-documented: the STEP 4 study (Rubino et al., 2021, JAMA) showed patients regained most lost weight within a year of discontinuation.
- Compounded GLP-1 formulations are not FDA-approved and are not equivalent to brand-name drugs like Wegovy or Zepbound. Patients should ask their clinician about the regulatory and safety distinctions.
- High view counts on TikTok do not reflect medical accuracy. Engagement metrics and clinical reliability have essentially no relationship to each other.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Brittany streetman · TikTok creator
20.9K views on this video
😝
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Brittany streetman, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.